- Home
- SVRA vs CIM Comparison
SVRA vs CIM Comparison
Compare SVRA & CIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRA | CIM |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | SVRA | CIM |
|---|---|---|
| Price | $5.56 | $12.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $7.33 | ★ $15.25 |
| AVG Volume (30 Days) | ★ 1.5M | 742.1K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 11.53% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.80 |
| Revenue Next Year | $430.87 | $2.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $9.85 |
| 52 Week High | $7.01 | $14.88 |
Technical Indicators
Market Signals| Indicator | SVRA | CIM |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 47.23 |
| Support Level | $5.47 | $12.53 |
| Resistance Level | $6.10 | $13.19 |
| Average True Range (ATR) | 0.28 | 0.30 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 84.27 | 45.34 |
Price Performance
Historical ComparisonAbout SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.